Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2003 Mar;79(929):127–132. doi: 10.1136/pmj.79.929.127

Thalidomide and its derivatives: emerging from the wilderness

J Gordon 1, P Goggin 1
PMCID: PMC1742651  PMID: 12697909

Abstract

Forty years on from its worldwide withdrawal, thalidomide is currently undergoing a remarkable renaissance as a novel and powerful immunomodulatory agent. Over the last decade it has been found to be active in a wide variety of inflammatory and malignant disorders where conventional therapies have failed. Recently, considerable progress has been made in elucidating its complex mechanisms of action, which include both anticytokine and antiangiogenic properties. However, in addition to its well known teratogenic potential, it has a significant side effect profile that leads to cessation of treatment in up to 30% of subjects. In response to this, two new classes of potentially safer and non-teratogenic derivatives have recently been developed. This review summarises the biological effects, therapeutic applications, safety profile, and future potential of thalidomide and its derivatives.

Full Text

The Full Text of this article is available as a PDF (132.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arora M., Wagner J. E., Davies S. M., Blazar B. R., Defor T., Enright H., Miller W. J., Weisdorf D. F. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7(5):265–273. doi: 10.1053/bbmt.2001.v7.pm11400948. [DOI] [PubMed] [Google Scholar]
  2. Bariol Carolyn, Meagher Alan P., Vickers Christopher R., Byrnes David J., Edwards Paul D., Hing Michael, Wettstein Antony R., Field Andrew. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease. J Gastroenterol Hepatol. 2002 Feb;17(2):135–139. doi: 10.1046/j.1440-1746.2002.02564.x. [DOI] [PubMed] [Google Scholar]
  3. Bauditz J., Wedel S., Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut. 2002 Feb;50(2):196–200. doi: 10.1136/gut.50.2.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Baughman Robert P., Judson Marc A., Teirstein Alvin S., Moller David R., Lower Elyse E. Thalidomide for chronic sarcoidosis. Chest. 2002 Jul;122(1):227–232. doi: 10.1378/chest.122.1.227. [DOI] [PubMed] [Google Scholar]
  5. Bennett Charles L., Schumock Glen T., Desai Apurva A., Kwaan Hau C., Raisch Dennis W., Newlin Rebecca, Stadler Walter. Thalidomide-associated deep vein thrombosis and pulmonary embolism. Am J Med. 2002 Nov;113(7):603–606. doi: 10.1016/s0002-9343(02)01300-1. [DOI] [PubMed] [Google Scholar]
  6. Blaschke G., Kraft H. P., Fickentscher K., Köhler F. Chromatographische Racemattrennung von Thalidomid und teratogene Wirkung der Enantiomere. Arzneimittelforschung. 1979;29(10):1640–1642. [PubMed] [Google Scholar]
  7. Browne P. V., Weisdorf D. J., DeFor T., Miller W. J., Davies S. M., Filipovich A., McGlave P. B., Ramsay N. K., Wagner J., Enright H. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2000 Oct;26(8):865–869. doi: 10.1038/sj.bmt.1702626. [DOI] [PubMed] [Google Scholar]
  8. Corral L. G., Haslett P. A., Muller G. W., Chen R., Wong L. M., Ocampo C. J., Patterson R. T., Stirling D. I., Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999 Jul 1;163(1):380–386. [PubMed] [Google Scholar]
  9. Corral L. G., Kaplan G. Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis. 1999 Nov;58 (Suppl 1):I107–I113. doi: 10.1136/ard.58.2008.i107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. D'Amato R. J., Loughnan M. S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082–4085. doi: 10.1073/pnas.91.9.4082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dmoszyńska Anna, Bojarska-Junak Agnieszka, Domański Damian, Roliński Jacek, Hus Marek, Soroka-Wojtaszko Maria. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma. Leuk Lymphoma. 2002 Feb;43(2):401–406. doi: 10.1080/10428190290006224. [DOI] [PubMed] [Google Scholar]
  12. Dredge Keith, Marriott J. Blake, Todryk Stephen M., Muller George W., Chen Roger, Stirling David I., Dalgleish Angus G. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol. 2002 May 15;168(10):4914–4919. doi: 10.4049/jimmunol.168.10.4914. [DOI] [PubMed] [Google Scholar]
  13. Ehrenpreis E. D., Kane S. V., Cohen L. B., Cohen R. D., Hanauer S. B. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology. 1999 Dec;117(6):1271–1277. doi: 10.1016/s0016-5085(99)70276-3. [DOI] [PubMed] [Google Scholar]
  14. Eriksson T., Björkman S., Höglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol. 2001 Aug;57(5):365–376. doi: 10.1007/s002280100320. [DOI] [PubMed] [Google Scholar]
  15. Fabro S., Smith R. L., Williams R. T. Toxicity and teratogenicity of optical isomers of thalidomide. Nature. 1967 Jul 15;215(5098):296–296. doi: 10.1038/215296a0. [DOI] [PubMed] [Google Scholar]
  16. Govindarajan R., Heaton K. M., Broadwater R., Zeitlin A., Lang N. P., Hauer-Jensen M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 2000 Aug 12;356(9229):566–567. doi: 10.1016/s0140-6736(00)02586-1. [DOI] [PubMed] [Google Scholar]
  17. Gutiérrez-Rodríguez O., Starusta-Bacal P., Gutiérrez-Montes O. Treatment of refractory rheumatoid arthritis--the thalidomide experience. J Rheumatol. 1989 Feb;16(2):158–163. [PubMed] [Google Scholar]
  18. Hamuryudan V., Mat C., Saip S., Ozyazgan Y., Siva A., Yurdakul S., Zwingenberger K., Yazici H. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998 Mar 15;128(6):443–450. doi: 10.7326/0003-4819-128-6-199803150-00004. [DOI] [PubMed] [Google Scholar]
  19. Hansen J. M., Carney E. W., Harris C. Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro. Reprod Toxicol. 1999 Nov-Dec;13(6):547–554. doi: 10.1016/s0890-6238(99)00053-2. [DOI] [PubMed] [Google Scholar]
  20. Haslett P. A., Klausner J. D., Makonkawkeyoon S., Moreira A., Metatratip P., Boyle B., Kunachiwa W., Maneekarn N., Vongchan P., Corral L. G. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients. AIDS Res Hum Retroviruses. 1999 Sep 1;15(13):1169–1179. doi: 10.1089/088922299310269. [DOI] [PubMed] [Google Scholar]
  21. Huizinga T. W., Dijkmans B. A., van der Velde E. A., van de Pouw Kraan T. C., Verweij C. L., Breedveld F. C. An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis. 1996 Nov;55(11):833–836. doi: 10.1136/ard.55.11.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Höglund P., Eriksson T., Björkman S. A double-blind study of the sedative effects of the thalidomide enantiomers in humans. J Pharmacokinet Biopharm. 1998 Aug;26(4):363–383. doi: 10.1023/a:1021008016719. [DOI] [PubMed] [Google Scholar]
  23. Iyer C. G., Languillon J., Ramanujam K., Tarabini-Castellani G., De las Aguas J. T., Bechelli L. M., Uemura K., Martinez Dominguez V., Sundaresan T. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Organ. 1971;45(6):719–732. [PMC free article] [PubMed] [Google Scholar]
  24. Jacobson J. M., Greenspan J. S., Spritzler J., Ketter N., Fahey J. L., Jackson J. B., Fox L., Chernoff M., Wu A. W., MacPhail L. A. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997 May 22;336(21):1487–1493. doi: 10.1056/NEJM199705223362103. [DOI] [PubMed] [Google Scholar]
  25. Kaplan G., Thomas S., Fierer D. S., Mulligan K., Haslett P. A., Fessel W. J., Smith L. G., Kook K. A., Stirling D., Schambelan M. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1345–1355. doi: 10.1089/08892220050140892. [DOI] [PubMed] [Google Scholar]
  26. Keesal N., Wasserman M. J., Bookman A., Lapp V., Weber D. A., Keystone E. C. Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol. 1999 Nov;26(11):2344–2347. [PubMed] [Google Scholar]
  27. Keifer J. A., Guttridge D. C., Ashburner B. P., Baldwin A. S., Jr Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity. J Biol Chem. 2001 Apr 10;276(25):22382–22387. doi: 10.1074/jbc.M100938200. [DOI] [PubMed] [Google Scholar]
  28. Kenyon B. M., Browne F., D'Amato R. J. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997 Jun;64(6):971–978. doi: 10.1006/exer.1997.0292. [DOI] [PubMed] [Google Scholar]
  29. Kruse F. E., Joussen A. M., Rohrschneider K., Becker M. D., Völcker H. E. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 1998 Jun;236(6):461–466. doi: 10.1007/s004170050106. [DOI] [PubMed] [Google Scholar]
  30. Marriott J. B., Westby M., Cookson S., Guckian M., Goodbourn S., Muller G., Shire M. G., Stirling D., Dalgleish A. G. CC-3052: a water-soluble analog of thalidomide and potent inhibitor of activation-induced TNF-alpha production. J Immunol. 1998 Oct 15;161(8):4236–4243. [PubMed] [Google Scholar]
  31. McHugh S. M., Rifkin I. R., Deighton J., Wilson A. B., Lachmann P. J., Lockwood C. M., Ewan P. W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995 Feb;99(2):160–167. doi: 10.1111/j.1365-2249.1995.tb05527.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Moller D. R., Wysocka M., Greenlee B. M., Ma X., Wahl L., Flockhart D. A., Trinchieri G., Karp C. L. Inhibition of IL-12 production by thalidomide. J Immunol. 1997 Nov 15;159(10):5157–5161. [PubMed] [Google Scholar]
  33. Molloy F. M., Floeter M. K., Syed N. A., Sandbrink F., Culcea E., Steinberg S. M., Dahut W., Pluda J., Kruger E. A., Reed E. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001 Aug;24(8):1050–1057. doi: 10.1002/mus.1109. [DOI] [PubMed] [Google Scholar]
  34. Moreira A. L., Sampaio E. P., Zmuidzinas A., Frindt P., Smith K. A., Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993 Jun 1;177(6):1675–1680. doi: 10.1084/jem.177.6.1675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Neben Kai, Mytilineos Joannis, Moehler Thomas M., Preiss Astrid, Kraemer Alwin, Ho Anthony D., Opelz Gerhard, Goldschmidt Hartmut. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood. 2002 Sep 15;100(6):2263–2265. [PubMed] [Google Scholar]
  36. Neiger B. L. The re-emergence of thalidomide: results of a scientific conference. Teratology. 2000 Dec;62(6):432–435. doi: 10.1002/1096-9926(200012)62:6<432::AID-TERA11>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  37. Newman C. G. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin Perinatol. 1986 Sep;13(3):555–573. [PubMed] [Google Scholar]
  38. Nishimura K., Hashimoto Y., Iwasaki S. (S)-form of alpha-methyl-N(alpha)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-alpha production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem Pharm Bull (Tokyo) 1994 May;42(5):1157–1159. doi: 10.1248/cpb.42.1157. [DOI] [PubMed] [Google Scholar]
  39. Ochonisky S., Verroust J., Bastuji-Garin S., Gherardi R., Revuz J. Thalidomide neuropathy incidence and clinico-electrophysiologic findings in 42 patients. Arch Dermatol. 1994 Jan;130(1):66–69. [PubMed] [Google Scholar]
  40. Oliver S. J., Cheng T. P., Banquerigo M. L., Brahn E. The effect of thalidomide and 2 analogs on collagen induced arthritis. J Rheumatol. 1998 May;25(5):964–969. [PubMed] [Google Scholar]
  41. Oliver S. J., Freeman S. L., Corral L. G., Ocampo C. J., Kaplan G. Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis. Clin Exp Immunol. 1999 Nov;118(2):315–321. doi: 10.1046/j.1365-2249.1999.01039.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Oliver S. J., Moreira A., Kaplan G. Immune stimulation in scleroderma patients treated with thalidomide. Clin Immunol. 2000 Nov;97(2):109–120. doi: 10.1006/clim.2000.4920. [DOI] [PubMed] [Google Scholar]
  43. doi: 10.1136/gut.50.suppl_2.a4. [DOI] [PMC free article] [Google Scholar]
  44. Parman T., Wiley M. J., Wells P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med. 1999 May;5(5):582–585. doi: 10.1038/8466. [DOI] [PubMed] [Google Scholar]
  45. Peterson P. K., Hu S., Sheng W. S., Kravitz F. H., Molitor T. W., Chatterjee D., Chao C. C. Thalidomide inhibits tumor necrosis factor-alpha production by lipopolysaccharide- and lipoarabinomannan-stimulated human microglial cells. J Infect Dis. 1995 Oct;172(4):1137–1140. doi: 10.1093/infdis/172.4.1137. [DOI] [PubMed] [Google Scholar]
  46. Peuckmann V., Fisch M., Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000 Aug;60(2):273–292. doi: 10.2165/00003495-200060020-00003. [DOI] [PubMed] [Google Scholar]
  47. Powell R. J., Gardner-Medwin J. M. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J. 1994 Dec;70(830):901–904. doi: 10.1136/pgmj.70.830.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Rajkumar S. Vincent, Gertz Morie A., Kyle Robert A., Greipp Philip R., Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group Current therapy for multiple myeloma. Mayo Clin Proc. 2002 Aug;77(8):813–822. doi: 10.4065/77.8.813. [DOI] [PubMed] [Google Scholar]
  49. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., du Randt M., Kaspar C., Goldberg C., Loew J. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood. 2001 Aug 15;98(4):958–965. doi: 10.1182/blood.v98.4.958. [DOI] [PubMed] [Google Scholar]
  50. Revuz J., Guillaume J. C., Janier M., Hans P., Marchand C., Souteyrand P., Bonnetblanc J. M., Claudy A., Dallac S., Klene C. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol. 1990 Jul;126(7):923–927. [PubMed] [Google Scholar]
  51. Rowland T. L., McHugh S. M., Deighton J., Dearman R. J., Ewan P. W., Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology. 1998 Jul;40(1):11–20. doi: 10.1016/s0162-3109(98)00010-1. [DOI] [PubMed] [Google Scholar]
  52. Rowland T. L., McHugh S. M., Deighton J., Ewan P. W., Dearman R. J., Kimber I. Selective down-regulation of T cell- and non-T cell-derived tumour necrosis factor alpha by thalidomide: comparisons with dexamethasone. Immunol Lett. 1999 Jun 1;68(2-3):325–332. doi: 10.1016/s0165-2478(99)00055-3. [DOI] [PubMed] [Google Scholar]
  53. Sabate J. M., Villarejo J., Lemann M., Bonnet J., Allez M., Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther. 2002 Jun;16(6):1117–1124. doi: 10.1046/j.1365-2036.2002.01273.x. [DOI] [PubMed] [Google Scholar]
  54. Sampaio E. P., Hernandez M. O., Carvalho D. S., Sarno E. N. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother. 2002 Feb;56(1):13–19. doi: 10.1016/s0753-3322(01)00147-0. [DOI] [PubMed] [Google Scholar]
  55. Sampaio E. P., Sarno E. N., Galilly R., Cohn Z. A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991 Mar 1;173(3):699–703. doi: 10.1084/jem.173.3.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Shannon E. J., Sandoval F. Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol. 1996 Feb;18(1):59–72. doi: 10.3109/08923979609007110. [DOI] [PubMed] [Google Scholar]
  57. Shek L. P. C., Lim D. L. C. Thalidomide in Behçet's disease. Biomed Pharmacother. 2002 Feb;56(1):31–35. doi: 10.1016/s0753-3322(01)00154-8. [DOI] [PubMed] [Google Scholar]
  58. Sheskin J. Further observation with thalidomide in lepra reactions. Lepr Rev. 1965 Oct;36(4):183–187. doi: 10.5935/0305-7518.19650036. [DOI] [PubMed] [Google Scholar]
  59. Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide. Int J Dermatol. 1980 Jul-Aug;19(6):318–322. doi: 10.1111/j.1365-4362.1980.tb00342.x. [DOI] [PubMed] [Google Scholar]
  60. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., Munshi N., Anaissie E., Wilson C., Dhodapkar M. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999 Nov 18;341(21):1565–1571. doi: 10.1056/NEJM199911183412102. [DOI] [PubMed] [Google Scholar]
  61. Singhal S., Mehta J. Thalidomide in cancer. Biomed Pharmacother. 2002 Feb;56(1):4–12. doi: 10.1016/s0753-3322(01)00146-9. [DOI] [PubMed] [Google Scholar]
  62. Stephens T. D., Fillmore B. J. Hypothesis: thalidomide embryopathy-proposed mechanism of action. Teratology. 2000 Mar;61(3):189–195. doi: 10.1002/(SICI)1096-9926(200003)61:3<189::AID-TERA6>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  63. Stevens R. J., Andujar C., Edwards C. J., Ames P. R., Barwick A. R., Khamashta M. A., Hughes G. R. Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol. 1997 Mar;36(3):353–359. doi: 10.1093/rheumatology/36.3.353. [DOI] [PubMed] [Google Scholar]
  64. Tavares J. L., Wangoo A., Dilworth P., Marshall B., Kotecha S., Shaw R. J. Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. Respir Med. 1997 Jan;91(1):31–39. doi: 10.1016/s0954-6111(97)90134-7. [DOI] [PubMed] [Google Scholar]
  65. Teo S. K., Harden J. L., Burke A. B., Noormohamed F. H., Youle M., Johnson M. A., Peters B. S., Stirling D. I., Thomas S. D. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos. 2001 Oct;29(10):1355–1357. [PubMed] [Google Scholar]
  66. Thiele A., Thormann M., Hofmann H. J., Naumann W. W., Eger K., Hauschildt S. A possible role of N-cadherin in thalidomide teratogenicity. Life Sci. 2000 Jun 16;67(4):457–461. doi: 10.1016/s0024-3205(00)00636-6. [DOI] [PubMed] [Google Scholar]
  67. Tramontana J. M., Utaipat U., Molloy A., Akarasewi P., Burroughs M., Makonkawkeyoon S., Johnson B., Klausner J. D., Rom W., Kaplan G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med. 1995 May;1(4):384–397. [PMC free article] [PubMed] [Google Scholar]
  68. Trapnell C. B., Donahue S. R., Collins J. M., Flockhart D. A., Thacker D., Abernethy D. R. Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther. 1998 Dec;64(6):597–602. doi: 10.1016/S0009-9236(98)90050-9. [DOI] [PubMed] [Google Scholar]
  69. Tseng S., Pak G., Washenik K., Pomeranz M. K., Shupack J. L. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996 Dec;35(6):969–979. doi: 10.1016/s0190-9622(96)90122-x. [DOI] [PubMed] [Google Scholar]
  70. Vasiliauskas E. A., Kam L. Y., Abreu-Martin M. T., Hassard P. V., Papadakis K. A., Yang H., Zeldis J. B., Targan S. R. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology. 1999 Dec;117(6):1278–1287. doi: 10.1016/s0016-5085(99)70277-5. [DOI] [PubMed] [Google Scholar]
  71. Vogelsang G. B., Farmer E. R., Hess A. D., Altamonte V., Beschorner W. E., Jabs D. A., Corio R. L., Levin L. S., Colvin O. M., Wingard J. R. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992 Apr 16;326(16):1055–1058. doi: 10.1056/NEJM199204163261604. [DOI] [PubMed] [Google Scholar]
  72. Vogelsang G. B., Hess A. D., Santos G. W. Thalidomide for treatment of graft-versus-host disease. Bone Marrow Transplant. 1988 Sep;3(5):393–398. [PubMed] [Google Scholar]
  73. Waters M. F., Laing A. B., Ambikapathy A., Lennard-Jones J. E. Treatment of ulcerative colitis with thalidomide. Br Med J. 1979 Mar 24;1(6166):792–792. doi: 10.1136/bmj.1.6166.792. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Wolkenstein P., Latarjet J., Roujeau J. C., Duguet C., Boudeau S., Vaillant L., Maignan M., Schuhmacher M. H., Milpied B., Pilorget A. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998 Nov 14;352(9140):1586–1589. doi: 10.1016/S0140-6736(98)02197-7. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES